Remsima acquires IBD indication in Canada, accelerating expansion into NA market
Celltrion announced it acquired an addition indication of inflammatory bowel disease(IBD) for its autoimmune disease therapy, antibody biosimilar ‘Remsima(local name: Inflectra)’ from the Health Canada on June 10(local time).
The company acquired sales approval of ‘Remsima’ on indications such a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
